The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
- PMID: 18397975
- PMCID: PMC2453048
- DOI: 10.1210/jc.2008-0304
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Abstract
Context: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to all microsomal P450s, can ameliorate the 21OHD phenotype and, therefore, could be a modifier gene.
Objectives: We sought to identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity.
Patients and methods: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [(14)C]progesterone to deoxycorticosterone and [(3)H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging.
Results: The A503V POR variant was found in 10 of 30 alleles, the same ratio as in the normal population. There were no significant differences in Michaelis constant, maximum velocity and maximum velocity/Michaelis constant of 21-hydroxylase activity supported by wild-type and A503V POR.
Conclusion: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.
Similar articles
-
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.J Clin Endocrinol Metab. 2009 Jan;94(1):89-95. doi: 10.1210/jc.2008-1174. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957504 Free PMC article.
-
Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension.BMJ Case Rep. 2020 Sep 29;13(9):e233942. doi: 10.1136/bcr-2019-233942. BMJ Case Rep. 2020. PMID: 32994263 Free PMC article.
-
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.Fundam Clin Pharmacol. 2007 Aug;21(4):399-410. doi: 10.1111/j.1472-8206.2007.00520.x. Fundam Clin Pharmacol. 2007. PMID: 17635179 Review.
-
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.Pharmacogenet Genomics. 2010 Nov;20(11):677-86. doi: 10.1097/FPC.0b013e32833f4f9b. Pharmacogenet Genomics. 2010. PMID: 20940534 Free PMC article.
-
P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.Sci Signal. 2012 Oct 23;5(247):pt11. doi: 10.1126/scisignal.2003318. Sci Signal. 2012. PMID: 23092891 Review.
Cited by
-
Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.Endocr Rev. 2022 Jan 12;43(1):91-159. doi: 10.1210/endrev/bnab016. Endocr Rev. 2022. PMID: 33961029 Free PMC article. Review.
-
The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.Endocr Rev. 2011 Feb;32(1):81-151. doi: 10.1210/er.2010-0013. Epub 2010 Nov 4. Endocr Rev. 2011. PMID: 21051590 Free PMC article. Review.
-
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.J Clin Endocrinol Metab. 2009 Jan;94(1):89-95. doi: 10.1210/jc.2008-1174. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957504 Free PMC article.
-
Steroidogenic electron-transfer factors and their diseases.Ann Pediatr Endocrinol Metab. 2021 Sep;26(3):138-148. doi: 10.6065/apem.2142154.077. Epub 2021 Sep 30. Ann Pediatr Endocrinol Metab. 2021. PMID: 34610701 Free PMC article.
-
Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.Drug Metab Dispos. 2011 Aug;39(8):1433-9. doi: 10.1124/dmd.111.038836. Epub 2011 May 11. Drug Metab Dispos. 2011. PMID: 21562147 Free PMC article.
References
-
- Miller WL, Morel Y 1989 Molecular genetics of 21-hydroxylase deficiency. Ann Rev Genet 23:371–393 - PubMed
-
- Speiser PW, White PC 2003 Congenital adrenal hyperplasia. N Engl J Med 349:776–788 - PubMed
-
- Jaaskelainen J, Levo A, Voutilainen R, Partanen J 1997 Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 82:3293–3297 - PubMed
-
- Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, Arnhold IJ, Mendonça BB 1998 Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 83:4416–4419 - PubMed
-
- Krone N, Braun A, Roscher AA, Knorr D, Schwartz HP 2000 Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85:1059–1065 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources